Development and validation of AMBLor as a novel prognostic biomarker for early stage melanoma
Following the recent discovery of two proteins, AMBRA1 and Loricrin, whose combined loss (AMLo) of expression in the epidermis overlying primary non-ulcerated early stage cutaneous melanomas predicts disease progression, NovoPath have been instrumental in the development and translation of this biomarker discovery into a novel immunohistochemical based prognostic test (AMBLor).
Funding secured through an NIHR i4i grant (exceeding £1 million) for which NovoPath is a co-investigator, has enabled the pre-clinical validation of novel IHC antibodies to AMBRA1 and Loricrin in association with AMLo Biosciences Ltd as well as the evaluation of AMBLor in AJCC stage I/II melanoma cohorts derived from internationally and geographically distinct regions. Figure 1 shows example images of IHC staining demonstrating maintenance and loss of AMBRA1 and Loricrin biomarkers.
NovoPath represents a key component in the delivery of much needed precision-based biomarkers to identify high versus low risk patient sub groups with early stage melanomas.
Useful Link:- https://amlo-biosciences.com/about